Where is Johnson & Johnson headquartered?

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is recorded with headquarters in CN in NovaPharmaNews public regulatory and sponsor datasets.

Is Johnson & Johnson publicly traded?

Johnson & Johnson is represented in our database primarily through regulatory marketing authorisation or trial sponsor records; it may not have a US listed ticker in SEC EDGAR.

What drugs are associated with Johnson & Johnson?

No drug profiles are currently linked to Johnson & Johnson; check pipeline programs or search the drug directory.

What clinical trials is Johnson & Johnson sponsoring?

Johnson & Johnson is linked to 7 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Johnson & Johnson as applicant?

No US patent records are currently linked to this company profile.

What pipeline phases does Johnson & Johnson have in our database?

Phase distribution from linked programs: phase 3: 7.

Where does NovaPharmaNews source data on Johnson & Johnson?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Johnson & Johnson data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Johnson & Johnson data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Johnson & Johnson data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Janssen Research & Pharmaceuticals Company Profile

Name: Janssen Research & intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: Raritan, USA
Founded: 2001
Employees: 95
Programs: 7
Drugs: 4
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Quick answer

Johnson & Johnson is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ventilator-Associated Pneumonia, Carcinoma, Squamous Cell, Erectile Dysfunction, Schizoaffective Disorder, Acute Coronary Syndrome. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (7).

Company snapshot

Explore Janssen’s innovative medical research and development practices, and see how Janssen is dedicated to the well-being of patients around the world.

7 active pipeline program(s) linked via ClinicalTrials.gov.
7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Janssen Research &. Not investment advice.

Top assets

View drugs (4) View projects (7)

Lead pipeline drugs

doripenem
approved
placebo
Marketed / approved
rivaroxaban
approved
trabectedin
approved

Active clinical programs

Doripenem Ventilator-Associated Pneumonia
Phase 3
JNJ-90301900 (NBTXR3) Carcinoma, Squamous Cell
Phase 3
Placebo Schizoaffective Disorder
Phase 3
Placebo Erectile Dysfunction
Phase 3

Congress & presentations

View all events (8)

Presentation Jun 5, 2026
Updated results from the open-label Phase I/Ib CHRYSALIS-2 study (NCT04077463) of amivantamab and lazertinib in non-small cell lung cancer
Congress Jun 5, 2026
ASCO 2026
Presentation Jun 2, 2026
Lazertinib as first-line therapy in EGFR-mutant NSCLC: updated overall survival from LASER301

Momentum

Proprietary activity score for Janssen Research &.

2 active signals

30 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 7 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 5 90d
Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Janssen Research &.

May 26, 2026 Clinical update
Doripenem — Phase 3
May 26, 2026 Clinical update
JNJ-90301900 (NBTXR3) — Phase 3
May 26, 2026 Clinical update
Placebo — Phase 3
May 26, 2026 Clinical update
Placebo — Phase 3
May 26, 2026 Clinical update
Rivaroxaban — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Janssen Research &?

Johnson & Johnson is a pharma organization headquartered in CN. Primary therapeutic focus areas include Ventilator-Associated Pneumonia, Carcinoma, Squamous Cell, Erectile Dysfunction, Schizoaffective Disorder, Acute Coronary Syndrome. NovaPharmaNews links 7 clinical program(s),
Is Janssen Research & publicly traded?

Janssen Research & appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.
What drugs does Janssen Research & develop or market?

We link 4 drug profile(s) where Janssen Research & is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/johnson-johnson-medical-pty-ltd#company-drugs.
What are the latest developments for Janssen Research &?

In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Janssen Research & focus on?

Janssen Research & focuses on Ventilator-Associated Pneumonia, Carcinoma, Squamous Cell, Erectile Dysfunction based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology

Infectious Disease

Quick answer

Company snapshot

Top assets

Lead pipeline drugs

Active clinical programs

Congress & presentations

Momentum

Signal breakdown

Recent activity

Quick answers

Therapeutic area distribution

Programs by therapeutic area

Stay Ahead in Pharma